PLOD2 and nonpapillary renal cell carcinoma: In a cohort of 156 metastatic ccRCC patients treated with nivolumab (an anti-PD-1 therapy), high PLOD2 expression was associated with increased sensitivity to immune checkpoint blockade (ICB) (Fig. S5C).